UNFO’s Introduction of Innovative Corrective Foot Brace for Newborns, Aimed Towards Elevating Pediatric Orthopedic Care in the U.S.
Israeli Doctor Looks Forward to Revolutionizing Treatment for Metatarsus Adductus (MTA) In Newborns by Replacing the Need for Casting and Surgical Intervention.
UNFO Med Ltd., the renowned manufacturer of the Universal Neonatal Foot Orthotics (UNFO) system, has announced plans to introduce a first-of-its-kind corrective foot brace for newborns. The objective is to treat various foot conditions, including Metatarsus Adductus (MTA). MTA is a common condition in newborns that is responsible for causing the front half of the foot, or forefoot, to turn inward.
In addition, it results in other conditions, including forefoot adduction, Metatarsus Varus, in-toeing, and skew foot. The development of a first-of-its-kind corrective foot brace for newborns marks a significant milestone in pediatric orthopedic care. It’s going to prove productive in replacing the need for casting and surgical intervention.
Metatarsus Adductus – abbreviated as MTA, refers to a congenital foot condition that affects approximately 7% of births. With one sibling suffering from this genetic anomaly, there’s a 12% increased chance of the next child being born with the condition. MTA causes the front half of the foot to turn inward as a result of an off-center deviation at the tarsometatarsal joints. If left untreated, the condition leads to an increased risk of foot deformities and foot pain. In addition, the child also starts suffering from problems with their gait, causing them to fall frequently.
Traditionally, addressing MTA in infants has been possible with casting and surgical intervention. However, casting proves extremely uncomfortable and painful for the child. Casting causes stress for both the infant and the parents. To alleviate this suffering, UNFO decided to explore the potential of an innovative corrective foot brace. The guidance of Israeli Dr. Izak Daizade has helped the development, with the objective of eliminating the necessity for casting and surgery. The corrective foot brace can provide fruitful, non-invasive, and highly effective alternatives for newborns.
Dr. Izak Daizade, founder and R&D director of UNFO Med Ltd, has dedicated over three decades to the care of newborns. In this period, he identified a critical gap in the treatment of MTA. He invested seven years in dedicated research and unveiled UNFO, shaped as a short-foot orthotic device worn below the ankle. The short foot orthotic device is engineered with precision to address the three-dimensional anatomic deformities. Also, it addresses misalignments in infants’ foot structures. UNFO is developed as a discreet, sandal-like design ensuring proper correction of the condition while providing gentle and comfortable care for infants. Dr. Daizade has treated over 15,000 patients with the UNFO brace, yielding a 95% rate of success.*
Dr. Izak Daizade, CEO of UNFO Med Ltd, has stated that as a pediatric orthopedic specialist, he aimed at providing the best possible care for newborns facing challenges, including Metatarsus Adductus. He sees UNFO’s corrective foot brace as a significant advancement in the approach of pediatric orthopedics. According to him, it is going to serve as a non-invasive solution for transforming the treatment of newborns born with MTA, and it will signify a new era of proactive and compassionate care. He is excited about how the innovative solution is going to have a positive impact on the lives of infants and their families across the U.S.
Dr. John Herzenberg, ranked in the top 1% of his field by U.S. News Top Doctors, is a world-renowned Clinical Professor of Orthopedic Surgery. He founded and directs the International Center for Limb Lengthening at the hospital’s Rubin Institute for Advanced Orthopedics and previously served as Director of Pediatric Orthopedics at Sinai Hospital. Recently retired, Dr. Herzenberg has successfully treated over thirty patients using UNFO. His research indicates that UNFO is well-tolerated and results in rapid correction of Metatarsus Adductus, making it particularly beneficial for very young infants. Previously, he relied on serial casting or Bebax orthoses..
UNFO, patented technology, and FDA-registered is now available for medical practitioners and orthopedic specialists in the United States. It’s available at Sinai Hospital in Baltimore and select healthcare facilities nationwide. Visit https://unfo-med.com to inquire about or learn more about the product.
* It’s vital to note that the 5% failure was not due to the failure of the device. What led to the failure was the parents’ failure to follow the proper therapy protocol provided by Dr. Daizade.
ABOUT UNFO Med Ltd:
UNFO Med Ltd. Has established itself at the forefront of pioneering pediatric orthopedic innovation. The company is committed to reshaping the landscape of early childhood healthcare. It aims to revolutionize treatment methodologies. UNFO has established itself in the field of medical science as an innovative solution for targeting and solving prevalent orthopedic conditions in infants and children. Esteemed medical experts, including a renowned Israeli pediatric orthopedic specialist, developed collaboratively with UNFO, the UNFO system to serve as the pinnacle of cutting-edge healthcare technology. It’s guaranteed to serve as an innovative approach to corrective foot care for newborns. For more info visit https://unfo-med.com/
Read more
How to Effectively Remove Food Stains on Baby Clothes?
3 Tips When Purchasing Baby Clothes
